trial

Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

NCTId NCT00395031
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 57 (actual)
Sponsored by Manhattan Psychiatric Center
Primary completion 2010-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
57 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2003-09
Primary completion
2010-01
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Ziprasidone

Sponsors

Manhattan Psychiatric CenterLead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Collaborator

Investigators

2
Saurabh Kaushik, M.D.Study Chair
Jean-Pierre Lindenmayer, M.D.Principal Investigator

Sites

1 total
New York, United States

Linked catalysts

1
Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophre — primary completion2010-01

Facts & assertions

4 sourced
Enrollment
57
Phase
PHASE2,PHASE3
Primary Completion Date
2010-01
Status
COMPLETED
relationships
The graph out of here
drug
Ziprasidone
drug
lead_sponsor
Manhattan Psychiatric Center
company
collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizoaffective Disorder
indication
Diabetes Mellitus
indication
Psychotic Disorders
indication
investigator
Saurabh Kaushik, M.D.
person
Jean-Pierre Lindenmayer, M.D.
person